Add BrightSurf on Google Email

Aligning Science Across Parkinson’s (ASAP) launches a second funding opportunity to accelerate novel tool development to advance Parkinson's disease research

The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.

Harbour BioMed and Insilico Medicine achieve strategic collaboration to advance AI-driven antibody discovery and development

The collaboration aims to accelerate antibody discovery and development using Harbour BioMed's technology platform and Insilico's AI expertise. The companies will develop next-generation AI-powered antibodies for immunology, oncology, and neuroscience, aiming to deliver innovative therapies with enhanced specificity, efficacy, and safety.

Metabolomics-driven approaches for identifying therapeutic targets in drug discovery

The article reviews metabolomics-driven approaches for identifying therapeutic targets in drug discovery, highlighting the challenges and limitations of current methods. Emerging technologies like single-cell metabolomics, artificial intelligence, and mass spectrometry imaging are explored to enhance target discovery.

Generative AI against diseases: Insilico Medicine announced Pharma.AI-powered HPK1 inhibitor series in peer-reviewed publication trilogy, as potential immunotherapy options

The study uses generative AI to identify and optimize potent and selective HPK1 inhibitors for immunotherapy. The results show a relatively balanced candidate compound with adequate in vitro ADME, in vivo PK properties, good oral bioavailability, and robust in vivo efficacy in various cancer models.

KAIST changes the paradigm of drug discovery with world's first atomic editing​

Researchers at KAIST successfully developed single-atom editing technology that maximizes drug efficacy by converting oxygen atoms into nitrogen atoms in furan compounds. This breakthrough technology enables selective editing of complex natural products or pharmaceuticals, opening new doors for building libraries of drug candidates.

Scientists from IOCB Prague help to improve medical drugs

Researchers at IOCB Prague successfully isolated the proteasome enzyme complex of the T. vaginalis parasite, enabling them to develop new medicines that can target this parasite without harming humans. This breakthrough has critical implications for treating trichomoniasis and reducing HIV risk.

Scientists at The Wistar Institute discover novel series of SARS-CoV-2 mpro inhibitors for potential new COVID-19 treatments

Scientists at The Wistar Institute have identified a novel series of SARS-CoV-2 Mpro inhibitors that effectively inhibit viral replication in vitro against multiple COVID variants. These compounds also synergize with existing antivirals, offering promise for developing future therapies.

SourceThe Wistar Institute·JournalAntimicrobial Agents and Chemotherapy·TypeExperimental study·DateOct 8, 2024

Pharmacology: Venomous crustacean from Mayan underwater caves provides new drug candidates

A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.

SourceGoethe University Frankfurt·JournalBMC Biology·TypeExperimental study·DateOct 4, 2024

Mount Sinai researchers introduce web portal empowering drug discovery and systems-level analysis of critical kinase-substrate interactions

KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·Journalnpj Systems Biology and Applications·DateOct 3, 2024

Quantum researchers come up with a recipe that could accelerate drug development

Researchers at the University of Copenhagen's Quantum for Life Centre have developed a new mathematical recipe to make quantum simulators more scalable and efficient. This breakthrough could speed up the development of new medicines from years to months by predicting how molecules behave in the human body before laboratory trials.

SourceUniversity of Copenhagen - Faculty of Science·JournalNature Communications·DateOct 3, 2024

Study combines data, molecular simulations to accelerate drug discovery

Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.

SourceUniversity of Cincinnati·JournalScience Advances·TypeComputational simulation/modeling·DateAug 30, 2024